Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06283966 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
A Phase 3 study of COPD (Chronic Obstructive Pulmonary Disease), sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5,000
- Enrollment target
- 20
- Study locations
NCT06283966: Recruiting Phase 3 study of COPD (Chronic Obstructive Pulmonary Disease), sponsored by AstraZeneca.
NCT06283966 is a Phase 3 study of COPD (Chronic Obstructive Pulmonary Disease) that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 5,000 participants, above the 179-participant average among 9 other COPD (Chronic Obstructive Pulmonary Disease) trials with a reported enrollment target (2693% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06283966, a Phase 3 study of COPD (Chronic Obstructive Pulmonary Disease), is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Primary Outcome
Evaluate the effect of combination triple therapy (BGF MDI 320/14.4/9.6 μg) compared with dual bronchodilator therapy (GFF MDI 14.4/9.6 μg) on cardiopulmonary outcomes.
Conditions Studied
Interventions
- DRUG BGF MDI 320/14.4/9.6 μg
- DRUG GFF MDI 14.4/9.6 μg
Study Locations (20)
Arizona
- Research Site - Gilbert
- Research Site - Glendale
- Research Site - Mesa
- Research Site - Mesa
- Research Site - Phoenix
- Research Site - Tempe
- Research Site - Tempe
- Research Site - Tucson
- Research Site - Tucson
Alabama
- Research Site - Athens
- Research Site - Cullman
- Research Site - Fairhope
- Research Site - Huntsville
- Research Site - Mobile
- Research Site - Sheffield
California
- Research Site - Apple Valley
- Research Site - Canoga Park
- Research Site - Castroville
- Research Site - Garden Grove
- Research Site - Gardena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2024-02-21 |
| Est. Completion | 2028-03-07 |
| Phase | Phase 3 |
What NCT06283966 shows while recruiting
NCT06283966 is an interventional study that assigns participants to a tested intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 179-participant average among 9 other COPD (Chronic Obstructive Pulmonary Disease) trials with a reported enrollment target (2693% higher).
The record links to 1 condition, with COPD (Chronic Obstructive Pulmonary Disease) appearing as the primary indexed condition, and to 2 interventions - of which BGF MDI 320/14.4/9.6 μg is the first listed.
NCT06283966 names 20 study sites across 3 states, led by Arizona, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT06283966 about?
NCT06283966 is a clinical study titled "A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease". This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
What is the current status of trial NCT06283966?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,000 participants. The study started on 2024-02-21. Estimated completion is 2028-03-07.
What conditions does trial NCT06283966 study?
This clinical trial studies the following conditions: COPD (Chronic Obstructive Pulmonary Disease).
What interventions are being tested in trial NCT06283966?
The interventions under investigation include: BGF MDI 320/14.4/9.6 μg (DRUG), GFF MDI 14.4/9.6 μg (DRUG).
Who is sponsoring clinical trial NCT06283966?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06283966 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COPD (Chronic Obstructive Pulmonary Disease)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06283966's enrollment target sits among peer trials
5,000 1st of 9 higher than 9 of 9 other COPD (Chronic Obstructive Pulmonary Disease) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COPD (Chronic Obstructive Pulmonary Disease) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
University of Michigan COPD Identification Through Lung Cancer Screening Cohort Study - MAP2
RECRUITING
-
Photon-counting CT in Chest Imaging
RECRUITING · NA
-
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
RECRUITING · NA
-
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
RECRUITING · Phase 4
-
Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation
RECRUITING · NA
-
Validation of Chronic Obstructive Pulmonary Disease (COPD) Algorithm
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI